Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Kuehne + Nagel on Brexit decision: “Free trade basis for prosperity”

  • No Brexit still the preferred solution
  • Risk of chaos following disorderly Brexit
  • Kuehne + Nagel well prepared to ensure flow of goods
Schindellegi / CH, January 16, 2019 – In response to the House of Commons vote in the UK, Dr. Detlef Trefzger, CEO of Kuehne + Nagel International AG, emphasises the importance of open markets.
“The House of Commons has made a historic decision which we need to respect. Kuehne + Nagel is committed to global free trade in principle which ensures prosperity for everyone. So from our perspective, “No Brexit” would be the preferred solution, since any form of Brexit is bound to increase trade barriers.
A disorderly Brexit is the worst solution. It will impose massive restrictions on the exchange of goods between the European Union and the United Kingdom. We appeal to the responsible bodies in London and Brussels to do the utmost to prevent this scenario. As far as we are concerned, we are focussed on ensuring the constant flow of goods for our customers”, says Trefzger.
Kuehne + Nagel has engaged customers and own industry experts over the past years to assess all possible impacts. In order to cope with the effects of a disorderly Brexit Kuehne + Nagel has taken steps to review all options to secure capacity on trade routes with Europe outside of the Kent corridor both by sea and air. Moreover, the company has commenced recruitment of additional customs clerks.
Kuehne + Nagel was asked to participate in the UK Government Cross Border Steering Group and will use this opportunity to define sustainable solutions as the set of Brexit conditions becomes clearer.
Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025